New research suggests that the cardiovascular health benefits of semaglutide may be more closely tied to the drug’s dosage than to the amount of weight a patient loses. A retrospective study published in npj Cardiovascular Health found that patients reaching higher maximum doses of semaglutide—1.7 mg or greater—experienced significantly lower risks of heart failure, cerebrovascular … Read more
The FDA’s approval of the Wegovy oral semaglutide pill in late December 2025 offers a needle-free weight management option, though it requires more rigorous dosing than the injectable version. According to Dr. Anthony Puopolo, Chief Medical Officer at LifeMD, the pill delivers the same molecule as the shot but faces biological barriers that demand strict … Read more
Nearly 4 in 10 patients with type 2 diabetes stop their GLP-1 medication within the first year of treatment, according to research presented at the Endocrine Society’s annual meeting, ENDO 2026. While discontinuation rates climb to nearly 6 in 10 by the end of two years, the data reveals a high frequency of patients restarting … Read more
GLP-1 receptor agonist medications, such as Ozempic and Wegovy, are associated with significantly lower rates of substance use disorders among patients with type 2 diabetes or obesity. A study published in Frontiers in Psychiatry found that patients taking these drugs showed reduced odds of alcohol, opioid, nicotine, and cocaine use disorders compared to similar patients … Read more
Research published in the journal Annals of Oncology indicates that GLP-1 receptor agonists (GLP-1 RAs) are associated with a 41% reduction in overall cancer risk among obese, non-diabetic adults. This study of more than 229,000 patients suggests these medications may offer significant benefits for cancer prevention beyond simple weight management. Which cancers are linked to … Read more
For years, the gold standard for medical knowledge has been the randomized controlled trial (RCT). While these trials are essential, they often exist in a “perfect” environment that doesn’t always mirror the messy, complex reality of daily clinical practice. That is changing. As presented at the latest EULAR Congress, the integration of real-world evidence (RWE) … Read more
Unlocking the Cellular Secrets of GLP-1 Weight Loss The rise of GLP-1 receptor agonists has transformed the landscape of weight management. While the clinical benefits of these medications are well-documented, the precise biological “nuts and bolts” occurring within our neurons have remained largely a mystery. A recent study conducted by researchers at the National Institutes … Read more
GLP-1 Drugs Aren’t Just for Weight Loss—They Could Revolutionize Workplace Productivity and Healthcare Systems From cutting sick days by half to slashing GP visits and boosting economic productivity, the next frontier of GLP-1 medications like Ozempic and Wegovy is far bigger than weight management. — ### The Weight-Loss Drugs That Could Fix a Productivity Crisis … Read more
Beyond Weight Loss: The New Frontier of GLP-1s in Addiction Recovery For years, GLP-1 receptor agonists like semaglutide have dominated headlines for their ability to transform metabolic health and trigger rapid weight loss. But a profound shift is happening in the medical community. We are moving past the “weight loss drug” label and entering the … Read more
The Rise of ‘Computational Social Listening’: How AI is Uncovering Hidden Drug Side Effects For decades, identifying drug side effects relied heavily on clinical trials and post-market reporting. Now, a new approach is gaining traction: analyzing the vast ocean of patient experiences shared on social media. Researchers at the University of Pennsylvania have pioneered a … Read more